These observations support the hypothesis that acquisition of TP53 or KRAS mutations provides MPN-BP ICs with a proliferative advantage, irrespective of the size of the mutant subclone present in the primary cells. This evidence concerns the gene TP53 and myeloproliferative neoplasm.